maois | CARLAT PUBLISHING

What You Need to Know About Gepirone (Exxua) | Benefits, Side Effects, and Review of Trials

September 27, 2024

In this video, Dr. Chris Aiken, Editor-in-Chief of The Carlat Psychiatry Report, provides a comprehensive review of Gepirone, also known as Exxua, a newly FDA-approved antidepressant for major depressive disorder in adults. Gepirone is unique due to its classification as an azipirone, a class of medications that work as serotonin 5-HT1A receptor agonists.

Stahl Goes Generic: 3 Reasons to use MAOIs

June 12, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

Stephen Stahl steps down from the industry-sponsored podium to remind us of 3 reasons to use an MAOI: Atypical depression, treatment-resistant depression, and social anxiety disorder.

Expert Q&A

Cardiovascular Psychiatry: Part 1

April 14, 2023

Margo C. Funk, MD, MA, FACLP

Margo C. Funk, MD, MA, FACLP.

Director of Cardiovascular Psychiatry, Vice Chair for Education, Residency Program Director, Department of Psychiatry, Brigham and Women’s Hospital, Boston, MA.

Dr. Funk has disclosed that in 2021, she received fees as a consultant for Acadia Pharmaceuticals. Dr. Aiken has reviewed this educational activity and has determined that there is no commercial bias as a result of this financial relationship.

Most psychiatric meds have cardiac risks. Dr. Funk tells us when to put the brakes on.

Psychopharm Commandment #6: MAOIs

March 20, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

When Further Medication Trials Seem Futile

June 10, 2020

Joseph Goldberg, MD

Joseph Goldberg, MD

Dr. Goldberg is a clinical professor of psychiatry at the Mount Sinai School of Medicine and maintains a private practice focused on mood disorders. He has published three psychiatric textbooks and is completing a fourth on psychopharmacology. Dr. Goldberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Joe Goldberg believes we do a disservice by shuffling patients through medication trials that have little chance of working. He shares techniques to engage patients, motivate change, combat demoralization, as well as his top pharmacologic strategies for highly resistant depression.